Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiome A ...
Second-highest abstract submissions on record, 96 live oral presentations, more than 400 posters, and global leaders ...
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs ...
RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
A prospective natural history study for GM1 and GM2: 24-month data from the PRONTO study – Poster number 132, providing insights into disease progression in GM1 and GM2 gangliosidoses. A Phase III ...
STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Presenting your poster at a Labroots Virtual Event can provide valuable research insights and feedback from peers in the comfort of your home or office. Every Labroots virtual event features a virtual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results